Instrument Inactif

Communiqués Aptose Biosciences Inc.

Actions

APS

CA03835T4081

Produits pharmaceutiques

Communiqués

01/07	Aptose Biosciences Announces Completion of Acquisition by Hanmi Pharmaceutical	AQ
15/06	Aptose Biosciences : Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation	PU
15/06	Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation	AQ
29/05	Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical	AQ
13/05	Aptose Biosciences: Q1 Earnings Snapshot	AQ
13/05	Aptose Biosciences : Reports First Quarter 2026 Results	PU
13/05	Aptose Reports First Quarter 2026 Results	AQ
30/04	Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical	AQ
01/04	Aptose Biosciences: Q4 Earnings Snapshot	AQ
31/03	Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 2025 Results and Corporate Highlights	AQ
23/03	Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan of Arrangement	AQ
20/03	Leading Independent Proxy Advisory Firm ISS Recommends Aptose Biosciences Shareholders Vote FOR Proposed Plan of Arrangement with Hanmi Pharmaceutical	AQ
19/03	Leading Independent Proxy Advisory Firm ISS Recommends Aptose Biosciences Shareholders Vote “FOR” Proposed Plan of Arrangement with Hanmi Pharmaceutical	AQ
24/02	Aptose Biosciences Announces Amendment to Arrangement Agreement and Details of Postponed Special Meeting of Shareholders	AQ
22/12	Aptose Biosciences Announces Rescheduling of Special Meeting of Shareholders to Approve the Acquisition by Hanmi Pending Final Clearance from SEC	AQ
19/12	Aptose Biosciences Announces Rescheduling of Special Meeting of Shareholders to Approve the Acquisition by Hanmi Pending Final Clearance from SEC	AQ
06/12	Aptose Biosciences : TUSCANY Study Demonstrates Safety and Efficacy of Tuspetinib plus Standard of Care Venetoclax and Azacitidine in Patients with Newly Diagnosed AML Ineligible for Induction Chemotherapy	PU
06/12	Aptose’s Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations	AQ
19/11	Aptose Biosciences Announces Arrangement Agreement for Acquisition by Hanmi Pharmaceutical	AQ
13/11	Aptose Biosciences: Q3 Earnings Snapshot	AQ
13/11	Aptose Reports Third Quarter 2025 Results	AQ
03/11	Aptose Tuspetinib Clinical Data from Ongoing TUSCANY Trial in Newly Diagnosed AML Selected for Presentation at the 2025 ASH Annual Meeting	AQ
16/10/25	Aptose Biosciences : ESH 2025 Poster - TUSCANY Study of Safety and Efficacy of Tuspetinib plus Standard of Care Venetoclax and Azacitidine in Study Participants with Newly Diagnosed AML Ineligible for Induction Chemotherapy	PU
16/10/25	Aptose’s Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML	AQ
22/09/25	Aptose and Hanmi Pharmaceutical Extend Loan Agreement to Continue Development of Tuspetinib in Triplet Therapy for AML	AQ